NasdaqCM:OPRX

Stock Analysis Report

Executive Summary

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers.

Rewards

Earnings are forecast to grow 128.82% per year

Risk Analysis

Highly volatile share price over past 3 months

Significant insider selling over the past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has OptimizeRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OPRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.9%

OPRX

-1.1%

US Healthcare Services

0.6%

US Market


1 Year Return

-18.4%

OPRX

26.5%

US Healthcare Services

20.8%

US Market

Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned 26.5% over the past year.

Return vs Market: OPRX underperformed the US Market which returned 20.8% over the past year.


Shareholder returns

OPRXIndustryMarket
7 Day7.9%-1.1%0.6%
30 Day1.0%1.8%2.5%
90 Day-37.7%2.2%4.9%
1 Year-18.4%-18.4%26.7%26.5%23.5%20.8%
3 Year311.4%311.4%89.2%88.5%46.5%37.0%
5 Year242.1%242.1%64.4%62.9%64.6%46.5%

Price Volatility Vs. Market

How volatile is OptimizeRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OptimizeRx undervalued compared to its fair value and its price relative to the market?

3.36x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: OPRX ($9.75) is trading above our estimate of fair value ($8.09)

Significantly Below Fair Value: OPRX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: OPRX is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: OPRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OPRX is good value based on its PB Ratio (3.4x) compared to the US Healthcare Services industry average (3.9x).


Next Steps

Future Growth

How is OptimizeRx forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

128.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: OPRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OPRX's is expected to become profitable in the next 3 years.

Revenue vs Market: OPRX's revenue (29.8% per year) is forecast to grow faster than the US market (7.4% per year).

High Growth Revenue: OPRX's revenue (29.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OptimizeRx performed over the past 5 years?

8.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OPRX is currently unprofitable.

Growing Profit Margin: OPRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OPRX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-0.2%).


Return on Equity

High ROE: OPRX has a negative Return on Equity (-3.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is OptimizeRx's financial position?


Financial Position Analysis

Short Term Liabilities: OPRX's short term assets ($37.9M) exceed its short term liabilities ($5.4M).

Long Term Liabilities: OPRX's short term assets ($37.9M) exceed its long term liabilities ($2.0M).


Debt to Equity History and Analysis

Debt Level: OPRX is debt free.

Reducing Debt: OPRX had no debt 5 years ago.


Balance Sheet

Inventory Level: OPRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if OPRX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OPRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is OptimizeRx's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage0.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of OptimizeRx's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Will Febbo (50yo)

3.8yrs

Tenure

US$923,138

Compensation

Mr. William J. Febbo, also known as Will, has been the Chief Executive Officer and Director of OptimizeRx Corp since February 22, 2016. Mr. Febbo is a Founder of Plexuus, an early stage payment processing  ...


CEO Compensation Analysis

Compensation vs Market: Will's total compensation ($USD923.14K) is above average for companies of similar size in the US market ($USD526.35K).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.4yrs

Average Tenure

54yo

Average Age

Experienced Management: OPRX's management team is considered experienced (3.4 years average tenure).


Board Age and Tenure

2.5yrs

Average Tenure

62.5yo

Average Age

Experienced Board: OPRX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: OPRX insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

BuyUS$5,77214 Nov 19
Ellen Vos
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares600
Max PriceUS$9.62
BuyUS$49,00013 Nov 19
Gus Halas
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares5,000
Max PriceUS$9.80
BuyUS$47,50006 Nov 19
William Febbo
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares5,000
Max PriceUS$9.50
SellUS$3,010,80027 Sep 19
Ronald Chez
EntityIndividual
Shares200,400
Max PriceUS$15.75
BuyUS$92,37427 Sep 19
Ronald Chez
EntityIndividual
Shares6,100
Max PriceUS$16.23
SellUS$81,76407 Jun 19
Wolverine Asset Management, LLC
EntityCompany
Shares5,310
Max PriceUS$16.05
BuyUS$92,63807 Jun 19
Wolverine Asset Management, LLC
EntityCompany
Shares6,577
Max PriceUS$14.85
SellUS$583,21922 May 19
AWM Investment Company Inc.
EntityCompany
Shares42,874
Max PriceUS$13.63
SellUS$1,120,22413 May 19
AWM Investment Company Inc.
EntityCompany
Shares82,126
Max PriceUS$13.76
SellUS$322,10819 Mar 19
AWM Investment Company Inc.
EntityCompany
Shares21,397
Max PriceUS$15.15
BuyUS$9,99820 Dec 18
Miriam Paramore
EntityIndividual
Role
President
President
Shares1,015
Max PriceUS$9.85
BuyUS$19,88020 Dec 18
William Febbo
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares2,000
Max PriceUS$9.94

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.8%.


Management Team

  • Will Febbo (50yo)

    CEO & Director

    • Tenure: 3.8yrs
    • Compensation: US$923.14k
  • Doug Baker (62yo)

    Chief Financial Officer

    • Tenure: 5.6yrs
    • Compensation: US$425.70k
  • Miriam Paramore (56yo)

    President

    • Tenure: 2.3yrs
    • Compensation: US$445.28k
  • Terry Hamilton (54yo)

    Senior Vice President of Sales

    • Tenure: 3.9yrs
    • Compensation: US$511.63k
  • James Brooks (50yo)

    Consultant

    • Tenure: 2.9yrs
    • Compensation: US$420.99k
  • Steve Silvestro

    Chief Commercial Officer

    • Tenure: 0.7yrs

Board Members

  • Pat Spangler (63yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$105.78k
  • Will Febbo (50yo)

    CEO & Director

    • Tenure: 3.8yrs
    • Compensation: US$923.14k
  • Gus Halas (68yo)

    Independent Chairman

    • Tenure: 2.5yrs
    • Compensation: US$130.90k
  • Lynn Vos (63yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$103.15k
  • Jay Pinney (62yo)

    Head of Medical Advisory Board

    • Tenure: 1.8yrs
    • Compensation: US$112.91k
  • Jim Lang (54yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: US$120.28k

Company Information

OptimizeRx Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OptimizeRx Corporation
  • Ticker: OPRX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$138.195m
  • Shares outstanding: 14.17m
  • Website: https://www.optimizerx.com

Number of Employees


Location

  • OptimizeRx Corporation
  • 400 Water Street
  • Suite 200
  • Rochester
  • Michigan
  • 48307
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OPRXNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJun 2005

Biography

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to med ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/14 00:21
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.